MannKind Corporation’s Post

May is #LupusAwarenessMonth! At Alumis, we're committed to improving the lives of people living with lupus by shedding light on this complex autoimmune disease and advancing clinical research. Recognizing the disparities in #lupus care, especially in under-resourced regions, we’re proud to be a member of the Lupus Research Alliance 's Lupus Accelerating Breakthroughs Consortium (Lupus ABC), to pioneer better endpoints and advance more impactful clinical trials. Learn more how you can get involved in supporting the lupus community: https://lnkd.in/esmUVvvw #LupusAwareness #LupusResearch

"World Snake Day" A day for one of most mesmerizing creatures on this planet. Snakes have always been associated with danger, while it stands true for many parts of the world, this venom is also carries immense potential for innovative therapeutics. Let's work towards raising awareness for snake bite and effective approach in treating the bite victims. Let's work towards researching innovative use of Snake venom for various therapeutic applications. #worldsnakeday#NTD#WHO

Today is #WorldKidneyDay, celebrated to raise awareness of the importance of good kidney health and the significant impact of kidney disease, the 10th leading cause of death globally. Mironid is working to transform the treatment landscape for patients with rare kidney disease. Our lead asset is a first-in-class small molecule LoAc® which directly targets the abnormally high kidney cAMP levels that drives cyst formation in Autosomal Dominant Polycystic Kidney Disease (#ADPKD), the most common hereditary kidney condition, with the potential to prevent new cyst formation and halt the growth of existing cysts. Learn more about ADPKD and how Mironid’s LoAc® compound works in this video! #KidneyDisease #RareDisease #Biopharma #DrugDevelopment

This #RareDiseaseDay, we're shining a light on the power of innovation and collaboration! Thanks to Indiana University researchers and the Innovation and Commercialization Office, groundbreaking therapy Burosumab is bringing hope to children fighting rare diseases like X-linked hypophosphatemia and tumor-induced osteomalacia. Read the inspiring #BetterWorldProject story here: https://bit.ly/3YaCiCh

Join us on Global #FattyLiverDay for a collaborative panel discussion with the The Association of Black Gastroenterologists and Hepatologists (ABGH) titled "Healing Your Liver: What Communities of Faith Need to Know About Liver Disease." This discussion will highlight the unique needs and challenges faced by diverse communities emphasizing the importance of trusted leaders in delivering tailored messaging. Together, we can #empower those impacted by #liverdisease to take proactive steps towards better #liverhealth. https://lnkd.in/ggFc64vw #ActNowScreenToday #FattyLiver #MASH

🌟 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 𝐢𝐬 𝐏𝐮𝐥𝐦𝐨𝐧𝐚𝐫𝐲 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡 🌟 This is a great opportunity to spotlight Noxon, one of our innovative portfolio companies dedicated to changing the treatment landscape for idiopathic pulmonary fibrosis (IPF). Noxon is advancing the fight against IPF with their novel drug, 3-cabamoyl-proxyl (3-CP), which targets fibrotic lung diseases with its unique antioxidant properties. This promising treatment aims to reduce inflammation and fibrosis, offering new hope for patients who face a median survival of just 2-3 years post-diagnosis. Next week, Firas Younis, the CEO of Noxon, will be attending the European Respiratory Society (ERS) conference in Vienna, one of the largest conferences for respiratory diseases. This marks a pivotal milestone as Noxon is achieving efficacy in animal models using the currently developed formulation for the oral slow release of the 3-CP API product. Pulmonary Fibrosis Awareness Month helps raise awareness about this serious condition and supports the ongoing search for more effective treatments. Discover how Noxon is making strides in this crucial area. Learn more about Noxon and their pioneering efforts in the battle against pulmonary fibrosis> https://lnkd.in/dBnA9xBE #PulmonaryFibrosis #PFMonth #InnovativeTreatment #Healthcare

📣 NEW! LightCure Consortium receives Horizon Europe Grant. 💡 Congenital Hyperinsulinism International (CHI) is excited to announce we are part of a new 11-member research consortium called LightCure. The LightCure Consortium is developing a targeted photodynamic therapy, that one day could be a promising treatment for congenital hyperinsulinism (HI). 💙 This project is made possible by a 72-month-long grant of just over €8.2M from the European Union research arm Horizon Europe and encompasses CHI’s work to strengthen patient engagement and raise worldwide awareness of HI and its myriad challenges. 🔗 You can find more information about this exciting project at https://lnkd.in/eVq-2Faa #hyperinsulinism #raredisease #congenitalhyperinsulinism #hypoglycemia | Hyperinsulinism | Congenital | HI | Hypoglycemia | Rare Disease

#NovoNordisk, renowned for #Wegovy and #Ozempic, is set to acquire #CardiorPharmaceuticals for a whopping $1.1B! This strategic move aims to bolster their portfolio in the battle against cardiovascular diseases. 🌍❤️ Based in Germany, Cardior is at the forefront of developing RNA-targeted therapies to prevent, repair, and even reverse heart disease - the leading cause of death globally. Their leading compound, CDR132L, is making waves in phase 2 trials, showing promise in halting and partially reversing heart damage. 🧬💔 With plans to launch a new phase 2 trial for chronic heart failure patients, Novo Nordisk is stepping up its game following the recent FDA nod for Wegovy in reducing cardiovascular risks. 💉👩⚕️ Stay tuned for how this acquisition shapes the future of heart health! #HeartHealth #PharmaNews #Innovation #Acquisition

To mark Rare Disease Day 2024, this week we are exploring four critical elements to sustaining rare disease innovation in Europe. Today focuses on requirement #3: Supportive P&R. Whether a medicine exists matters little for patients who cannot receive it because it is not reimbursed. Reimbursement is also key for manufacturers who rely on the sale of medicines to recover their considerable investment in development and to support their future pipeline. Continued innovation and access in rare disease in Europe relies on country-level pricing and reimbursement (P&R) approaches that can recognise and reward promising orphan developments. But this is by no means simple since many extremely novel, transformative treatments fall foul of traditional P&R systems designed for chronic therapies in common conditions. One example is cell and gene therapies. These unique treatments present immense value owing to their one-time, potentially curative profile. They also come with a significant price tag, complex delivery, and an inevitable degree of uncertainty around long-term benefit. In our recent paper for the Alliance for Regenerative Medicines (ARM), Dolon's Managing Director, Adam Hutchings, explores these challenges and their implications for P&R, patient access, and the sustainability of ATMP innovation in Europe. In particular, we focus on innovative contracting as an opportunity to mitigate these challenges as well as recent learnings from manufacturers’ experience in negotiating these. P&R frameworks need to evolve with science if they are to fully reflect the value of emerging therapies to patients and health systems alike. Failure to do so will come at the expense of patients and health systems today, and Europe’s standing as a global centre for innovation in the longer term. Read on to learn more: https://bit.ly/42UC0Uf #RareDiseaseDay2024 #RareDiseaseDay #RDD2024 #LightUpForRare #ShareYourColours #RareDiseases #RareDiseaseAwareness #RareDiseaseInnovation #Dolon

What is RAY? RAY: Research Accelerated by You is a lupus data platform where people with lupus and caregivers share information about their lupus experience to help researchers accelerate the development of new treatments and improve disease outcomes. You can be a ray of hope to ensure a bright future for lupus research by sharing your lupus experience. https://ow.ly/3u2G50RfiSo